Cancer cells interfere the synthesis of MHC class I molecule through decreased expression of β2M and loss of functional β2M as a response to immunotherapy, contributing to the acquired resistance (21, 22), which was illustrated by several studies of melanoma. Here, B2M is linked to cancer.